FCM
Farallon Capital Management Portfolio holdings
AUM
$21.3B
This Quarter Return
-2.68%
1 Year Return
+23.12%
3 Year Return
+87.19%
5 Year Return
+183.94%
10 Year Return
+836.54%
AUM
$12.2B
AUM Growth
+$12.2B
(-15%)
Cap. Flow
-$622M
Cap. Flow
% of AUM
-5.09%
Top 10 Holdings %
Top 10 Hldgs %
49.99%
Holding
122
New
16
Increased
44
Reduced
27
Closed
23
Top Buys
| 1 |
AGN
Allergan plc
AGN
|
$881M |
| 2 |
IAC Inc
IAC
|
$318M |
| 3 |
Alibaba
BABA
|
$280M |
| 4 |
Alphabet (Google) Class C
GOOG
|
$131M |
| 5 |
BPL
Buckeye Partners, L.P.
BPL
|
$131M |
Top Sells
| 1 |
RHT
Red Hat Inc
RHT
|
$964M |
| 2 |
APC
Anadarko Petroleum
APC
|
$738M |
| 3 |
ARRY
Array Biopharma Inc
ARRY
|
$394M |
| 4 |
Booking.com
BKNG
|
$130M |
| 5 |
Equifax
EFX
|
$117M |
Sector Composition
| 1 | Healthcare | 42.86% |
| 2 | Technology | 14.15% |
| 3 | Communication Services | 11.41% |
| 4 | Industrials | 6.61% |
| 5 | Consumer Discretionary | 6.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ascendis Pharma
ASND
$12B
| $149M | 1.13% |
1,550,000
+10,000
| +0.6% | +$963K |
|
27
Palo Alto Networks
PANW
$128B
| $124M | 0.94% |
+610,000
| New | +$124M |
|
28
Alnylam Pharmaceuticals
ALNY
$58.7B
| $121M | 0.91% |
1,500,000
+400,000
| +36% | +$32.2M |
|
29
Iovance Biotherapeutics
IOVA
$792M
| $110M | 0.83% |
6,025,000
+300,000
| +5% | +$5.46M |
|
30
AstraZeneca
AZN
$255B
| $106M | 0.8% |
2,375,785
-1,724,215
| -42% | -$76.8M |
|
|
MYOK
31
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $106M | 0.8% |
2,030,397
+30,397
| +2% | +$1.59M |
|
32
Sea Limited
SE
$107B
| $104M | 0.79% |
3,375,000
| – | – |
|
33
TransUnion
TRU
$16.8B
| $102M | 0.77% |
1,255,138
-417,205
| -25% | -$33.8M |
|
|
XLRN
34
DELISTED
Acceleron Pharma Inc.
XLRN
| $94.8M | 0.72% |
2,400,000
+25,000
| +1% | +$988K |
|
|
35
Equifax
EFX
$29.2B
| $89.3M | 0.67% |
635,056
-828,723
| -57% | -$117M |
|
|
GWR
36
DELISTED
Genesee & Wyoming Inc.
GWR
| $86.5M | 0.65% |
782,673
+7,673
| +1% | +$848K |
|
|
ALDR
37
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $78.6M | 0.59% |
+4,165,000
| New | +$78.6M |
|
|
GBT
38
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $78.2M | 0.59% |
1,612,069
+487,069
| +43% | +$23.6M |
|
|
BRMK
39
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $77.3M | 0.58% |
+75,000,000
| New | +$77.3M |
|
40
Enanta Pharmaceuticals
ENTA
$191M
| $76.6M | 0.58% |
1,274,212
+314,212
| +33% | +$18.9M |
|
41
AbbVie
ABBV
$375B
| $75.7M | 0.57% |
+1,000,000
| New | +$75.7M |
|
|
ZGNX
42
DELISTED
Zogenix, Inc.
ZGNX
| $70.1M | 0.53% |
1,750,000
-250,000
| -13% | -$10M |
|
43
Grifois
GRFS
$6.53B
| $62.4M | 0.47% |
3,113,222
+33,139
| +1% | +$664K |
|
|
44
Booking.com
BKNG
$181B
| $61.1M | 0.46% |
31,139
-66,310
| -68% | -$130M |
|
|
CY
45
DELISTED
Cypress Semiconductor
CY
| $57.5M | 0.43% |
+2,464,966
| New | +$57.5M |
|
46
CVS Health
CVS
$92.5B
| $56.8M | 0.43% |
900,000
+77,500
| +9% | +$4.89M |
|
|
RDUS
47
DELISTED
Radius Health, Inc.
RDUS
| $52.9M | 0.4% |
2,054,486
+11,337
| +0.6% | +$292K |
|
|
SAGE
48
DELISTED
Sage Therapeutics
SAGE
| $52.3M | 0.4% |
372,800
-127,200
| -25% | -$17.8M |
|
49
Zymeworks
ZYME
$1.06B
| $42.9M | 0.32% |
1,731,500
-24,970
| -1% | -$619K |
|
|
TVRD
50
Tvardi Therapeutics, Inc. Common Stock
TVRD
$267M
| $39.3M | 0.3% |
2,150,000
+1,198,674
| +126% | +$21.9M |
|